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Abstract
MicroRNAs (miRNAs) might be considered both predictors and players of cancer development. The aim of the present 
report was to investigate whether many years before the diagnosis of breast cancer miRNA expression is already 
disregulated. In order to test this hypothesis, we compared miRNAs extracted from leukocytes in healthy women 
who later developed breast cancer and in women who remain healthy during the whole 15-year follow-up time. 
Accordantly, we used a case–control study design nested in the hOrmone and Diet in the ETiology of breast cancer 
(ORDET) prospective cohort study addressing the possibility that miRNAs can serve as both early biomarkers and 
components of the hormonal etiological pathways leading to breast cancer development in premenopausal women. 
We compared leukocyte miRNA profiles of 191 incident premenopausal breast cancer cases and profiles of 191 women 
who remained healthy over a follow-up period of 20 years. The analysis identified 20 differentially expressed miRNAs 
in women candidate to develop breast cancer versus control women. The upregulated miRNAs, miR-513-a-5p, miR-
513b-5p and miR-513c-5p were among the most significantly deregulated miRNAs. In multivariate analysis, miR-513a-5p 
upregulation was directly and statistically significant associated with breast cancer risk (OR = 1.69; 95% CI 1.08–2.64; 
P = 0.0293). In addition, the upregulation of miR-513-a-5p displayed the strongest direct association with serum 
progesterone and testosterone levels. The experimental data corroborated the inhibitory function of miR-513a-5p on 
progesterone receptor expression confirming that progesterone receptor is a target of miR-513a-5p. The identification 
of upregulated miR-513a-5p with its oncogenic potential further validates the use of miRNAs as long-term biomarker of 
breast cancer risk.
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Introduction
Recent advances in high-throughput technology for gene 
expression led to the discovery that most human transcriptional 
regulatory units are non-coding RNAs (1). These RNA molecules 
do not encode proteins but have important structural, catalytic 
or regulatory functions, including regulation of gene expression 
involved in important functions. One such non-coding RNAs, 
microRNAs (miRNAs), are small RNA molecules (on average 22 
nucleotides in length) that are involved in the modulation of, 
among others, hormone and metabolic pathways through post-
transcriptional gene silencing (2,3). MicroRNAs may play a role 
in cancer progression functioning as oncogenes or tumor sup-
pressors (4–6). At the same time, miRNAs have been recently 
indicated as non-invasive biomarkers for early detection of 
cancer (7). In a previous report from our group, we observed 
differences in leukocytes miRNA expression between healthy 
postmenopausal women who later became affected with breast 
cancer and in women who did not develop the disease during 
the same 20-year follow-up period (8). This provides strong evi-
dence to the role of leukocyte miRNAs as early, long-term bio-
markers of breast cancer.
The present investigation aimed to study miRNAs not only 
as biomarkers of breast cancer risk, this time in premeno-
pausal women, but also to characterize their functional activ-
ity to unravel their specific role in breast cancer development. 
Previously conducted prospective cohort studies, including the 
hOrmone and Diet in the ETiology of breast cancer (ORDET) study, 
observed that endogenous sex steroids were directly (estrogens 
and androgens) or inversely (progesterone) associated with risk 
of breast cancer (9–14). Thus, we expected to observe that the 
early disregulated miRNAs had specific function in modulating 
the steroid hormone synthesis and/or metabolism associated 
with risk or protection of breast cancer. 
To test this working hypothesis, we compared leukocyte 
miRNA profiles of healthy premenopausal women who subse-
quently became affected with breast cancer with women who 
remained healthy.
The present investigation was conducted in two succeeding 
steps: (i) a case–control study nested in the ORDET prospective 
cohort over a follow-up period of 20 years; (ii) an experimental 
study to validate the observational study results. As a part of 
the first step, we have validated the ORDET study findings in a 
different cohort, the METABRIC study (15) where molecular pro-
file of tumor and non-tumor tissue samples collected from 1375 
breast cancer patients have been extensively characterized.
Materials and methods
Study design and population
The study has been conducted in the context of the ORDET prospective 
cohort study.
The ORDET cohort was established in Northern Italy between June 
1987 and June 1992, in which 10 786 healthy women aged 35–69 years were 
enrolled (16). They were all residents of the Varese province, an area cov-
ered by the population-based Lombardy Cancer Registry (17). They had 
heard about the study through the media, at public meetings and volun-
teered to participate. At recruitment, we measured anthropometric vari-
ables and collected demographic information and blood samples. Because 
the study’s original focus was on endogenous hormones in relation to 
breast cancer risk, we also applied stringent inclusion criteria and highly 
standardized conditions on the collection of biologic samples.
Information on cancer outcomes available from the Lombardy Cancer 
Registry has been linked to the ORDET cohort to identify incident breast 
cancer cases up to December 31, 2006 (18) for a median follow-up time of 
15.4 years. The ORDET file was also linked to the Varese residents’ file to 
check participants’ vital status. Participants were censored at the time of 
cancer diagnosis, death or loss to follow-up, whichever came first. Case 
subjects were women who developed breast cancer after their recruitment 
into the ORDET cohort and before the end of the follow-up. We randomly 
chose one control for each case, from appropriate risk sets consisting of all 
cohort members who satisfied the matching criteria. Matching character-
istics were age (±3 years) at enrolment and date of recruitment (±180 days). 
An incidence density sampling protocol for control selection was used, 
such that controls could include subjects who became a case later, while 
each control subject could also be sampled more than once (19). Selecting 
controls with incidence density sampling provides important advantages 
such as the possibility to obtain a direct estimate of the rate ratio and to 
calculate unbiased estimates where biases can always occur due to differ-
ential loss to follow-up among the exposed versus unexposed controls (20).
Women were classified as premenopausal if they had at least one 
menstruation in the 6 months prior to recruitment. The analysis included 
191 incident invasive breast cancer cases in premenopausal status at 
recruitment and 191 matched control subjects.
This study was approved by the Ethical Review Board of the National 
Cancer Institute of Milan (Italy).
Biomarker stability and blood collection
A relevant feature of miRNAs is their remarkable stability, which indicates 
their use as biomarkers in a number of different tissues (21,22). In this 
study, we evaluated the miRNA expression profile of leukocytes derived 
from buffy coats collected at recruitment.
Blood samples were drawn after overnight fasting between 7:30 AM 
and 9:00 AM from each premenopausal woman. Women were timed to 
be collected between the 20th and 24th day of their menstrual cycle (i.e. 
during the mid luteal phase). For further verification of their luteal phase 
during blood collection, women were given a postcard to report the date of 
the subsequent bleeding after the blood drawing (13). Blood samples from 
each breast cancer case and related control were handled identically and 
assayed together on the same day and in the same run. All samples were 
taken out of the freezer simultaneously and sent to laboratory in the same 
parcel on dry ice. They were stored at –80°C until the bioassays included 
in the present report. Laboratory personnel were blinded to case–control 
status.
Laboratory methods
RNA extraction, labeling and microarray hybridization
Leucocytes were lysed in 1  ml of TRIZOL Reagent, a lysis reagent from 
Ambion, according to the manufacturer’s instructions. The concen-
tration and purity of total RNA were assessed using a NanoDrop 1000 
Spectrophotometer (NanoDrop Technologies). Total RNA (100  ng) 
was labeled, hybridized to human microRNA Microarray V2 (Agilent 
Technologies), and scanned with Agilent DNA Microarray Scanner (P/N 
G2565BA) according to the manufacturer’s instructions. Feature Extraction 
Software (Version 10.5) was used for data extraction from raw microar-
ray image files using the microRNA_105_Dec08 FE protocol. This miRNA 
Agilent expression profile was submitted to the Gene Expression Omnibus 
(GEO) with the accession number GSE54470. Minimum information about 
a microarray gene experiment (MIAME) guidelines were followed as 
instructions. Furthermore, representative RNA preparations were evalu-
ated for integrity using the 2100 Bioanalyzer RNA 6000 Nano Kit (Agilent 
Technologies; data not shown). We also assessed the expression of miRNA-
223 in randomly selected samples by Northern blot analysis. miR223 is 
highly specific for hematopoietic cells and constitutes a regulator of mye-
lopoiesis (23). The blot was hybridized with a [32P]gATP-radiolabeled LNA 
oligonucleotide complementary to miRNA-223 sequence. The specificity 
and strength of hybridization of ORDET RNA samples was as good as that 
of human promyelocytic HL60 cells treated with retinoic acid (10-6 mol/l), 
a known inducer of miRNA-223. 
Abbreviations 
FDR  false discovery rate
miRNAs  microRNAs
PR  progesterone receptor
TGS  total gene signal
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Hormone assay
Stability and reliability of the ORDET collection method for sex steroids 
in premenopausal women have been previously described (13). Control of 
analytic error was based on the inclusion of two standard samples.
All samples were assayed in duplicate, by using commercially avail-
able kits following the manufacturer’s instructions. Plasma sex steroid 
measurements (testosterone, estradiol and progesterone) were conducted 
by Centro Medico Diagnostico Emilia (Bologna, Italy). For testosterone and 
progesterone we used Coat-A-Count procedure, a solid-phase radioim-
munoassay (Diagnostic Products Corporation, Los Angeles, CA) and for 
estradiol, Orion Diagnostica SPECTRIA Sensitive RIA test, a coated-tube 
radioimmunoassay (Orion Diagnostica Oy, Espoo, Finland). Quality con-
trol was done at three concentrations for total testosterone and at four 
concentrations for total estradiol and progesterone. Intra- and inter-assay 
coefficients of variation were, respectively, 4.2–4.6% and 8.0–9.1% for total 
testosterone; 4.3–8.6% and 6.0–15.2% for free testosterone; 2.2–7.0% and 
6.8–13.8% for DHEAS; 6.3–8.7% and 5.3–10.6% for progesterone; 2.7–3.5% 
and 4.4–9.6% for SHBG; 1.5–2.7% and 2.4–4.8%. In each batch, quality-
control samples were evaluated in quadruplicate. Average between-batch 
coefficients of variation for high and low concentrations were 7.4 and 
16.4% for estradiol, 8.7 and 18.5% for total testosterone and 5.3 and 10.6% 
for progesterone. Serum levels of progesterone were compatible with ovu-
latory cycles, ranging between 5.3 and 21.5 ng/ml in control subjects and 
between 4.8 and 20.8 ng/ml in incident breast cancer cases; 6.3–8.7% and 
5.3–10.6% for progesterone and 6.3– 8.7% and 5.3–10.6% for progesterone.
Microarray data analysis
Data were verified and extracted by the Agilent Extraction 10.7.3.1 software 
and analyzed using an inhouse built routines by Matlab (The MathWorks 
Inc.). Background-subtracted signal of 851 human miRNA assays was used 
in the study. All arrays were quantile normalized, assuming that all sam-
ples were measured and analyzed under the same condition, enforcing all 
the arrays to assume the same mean distribution. The Pearson coefficient 
was calculated to assess the correlation between technical replicates of 
some randomly chosen samples.
We fitted a linear model to the expression values for each miRNA, to 
assess the significance of differential expression between case and con-
trol. In addition, we used empirical Bayes methods implemented in the 
Linear Models for MicroArrays (LIMMA) package to construct moderated t 
statistics and incorporated the statistical tools to adjust for the multiplic-
ity of the tests. The Benjamini method (24) was used to control for false 
discovery. We considered the linear model including the matched case–
control study design, the case–control status and the error term.
Statistical methods
Data pre-processing and differential expression analysis were done using 
the Bioconductor AgiMicroRna package (25). The total gene signal (TGS) 
provided by the Agilent Feature Extraction image analysis software was 
used as the quantitative measure of miRNA expression. The TGS provided 
by the Agilent Feature Extraction image analysis software was used as the 
quantitative measure of miRNA expression. We set all negative TGS values 
to 0.5 before log transformation, so that the log ratios are shrunk toward 
zero at lower intensities. The miRNA expression data (i.e. TGS) were quan-
tile normalized before determining differential expression. The data were 
analyzed using the R software package. For differential expression analysis, 
the AgiMicroRna package incorporates the linear model with matched pair 
features from the Bioconductor LIMMA package (26). The LIMMA approach 
fits a linear model to the expression value for each miRNA to assess the 
significance of differential expression between different experimental con-
ditions. In addition, the method uses empirical Bayes methods (27) to con-
struct moderated t statistics and incorporates statistical tools to adjust for 
multiple testing. The Benjamini method (24) was used to control for false 
discovery rate (FDR), and we ranked the miRNAs according to FDR. We con-
sidered the top-ranked 20 miRNAs and investigated the upregulated and 
downregulated miRNAs identified from premenopausal samples. At first, 
each object is assigned to its own cluster and then the algorithm proceeds 
iteratively. At each stage, the two most similar clusters are combined to 
form a larger cluster, continuing until there is just a single cluster. At each 
stage, distances between clusters are computed by the Lance–Williams dis-
similarity update formula. Details about the clustering algorithm are given 
in the book by Kaufman and Rousseeuw (28). This clustering method parti-
tions the dataset into clusters, in which similar miRNA expression patterns 
are assigned to the same cluster.
Several breast cancer risk factors were used in a univariate and multi-
variate logistic regression models to predict positive or negative z-scores 
of normalized signal intensity of specific miRNAs. Confidence intervals 
were set at 95%. In the regression models the variables with a P value less 
than 0.05 were included in a multivariate model. Variables with a P value 
less than 0.1 in the multivariate model were considered significant.
All regression analyses were performed by Matlab (The MathWorks).
Target prediction was assessed by using several prediction software 
included in the web server tool MirWalk2.0 (http://zmf.umm.uni-heidel-
berg.de/apps/zmf/mirwalk2/). Prediction was considered reliable if con-
firmed by at least three different software. Predicted targets were used for 
pathway analysis.
In order to validate the prediction reported in the ORDET patients, we 
performed a validation analysis in the patients from a different cohort, 
the METABRIC cohort (15), a cohort of 1359 molecularly well characterized 
breast cancer patients and carried out a functional analyses separating 
the patient low and high expression levels of the miRNAs selected. In par-
ticular, we conducted a correlation analysis on matched miRNA\mRNA 
samples from METABRIC cohort.
Cell cultures and transfection
Human luminal breast cancer cell lines MCF-7, T47D, ZR-75-1 and BT-474 
were cultured in Dulbecco's modified Eagle's medium (Invitrogen) with 10% 
(v/v) fetal bovine serum; cells were grown at 37°C in a balanced air humidi-
fied incubator with 5% CO2. All fresh cell lines were purchased from ATCC 
that has authenticated them by STR genotyping with Promega PowerPlex® 
1.2 system and the Applied Biosystems Genotyper 2.0 software for analysis 
of the amplicons. The cells were maintained in culture no more than six pas-
sages. All the cell lines have been tested by PCR/IF for Mycoplasma presence.
For mature miR-513a-5p expression, we used mirVana miRNA Mimic 
Negative Control #1 (ThermoFisher) and miR-513a-5p mirVana miRNA 
Mimic (ThermoFisher) at final concentration of 5 nM.
Cells were transfected using Lipofectamine RNAiMAX (Invitrogen) 
according to the manufacturer’s instructions.
During hormone treatments, cells were serum-starved for 12–16 h in 
Dulbecco's modified Eagle's medium (Invitrogen), and then treatments 
were performed in Dulbecco's modified Eagle's medium with 0.5% bovine 
serum albumin.
All hormones were dissolved in 100% ethanol and used at a final con-
centration of 10 nM. The hormones used were progesterone (P4; Sigma) 
and 17b-estradiol (E2, Sigma).
MCF-7 cell line viability assay
Cell viability was evaluated using the ATPlite™ Luminescence Assay 
System and following the manufacturer’s instructions. Luminescence was 
read by the EnSpire® Multimode Plate Reader (PerkinElmer, Whitman, MA).
Total RNA extraction from cells and reverse 
transcriptase
Total RNA was extracted using the TRIZOL Reagents (GIBCO). One micro-
gram of total RNA was reverse-transcribed at 37°C for 60 min in the pres-
ence of random hexamers and Moloney murine leukemia virus reverse 
transcriptase (Invitrogen). Specific oligonucleotides for the genes listed 
in Supplementary Table 2, available at Carcinogenesis Online, for RTq-PCR 
analyses. GAPDH, progesterone receptor (PR) and ATP1B1 genes expres-
sions were measured by RTq-PCR using the Sybr Green assay (Applied 
Biosystems) on a StepOne instrument (Applied Biosystems).
Small amount of RNA (10  ng) was reverse-transcribed using the 
TaqMan microRNA Reverse Transcription Kit (Applied Biosystems). 
Reverse transcription was carried out in a final volume of 10 ul using ABI 
Prism 7000 Sequence Detection System (Applied Biosystems). The PCR 
Reactions were initiated with a 10-min incubation at 95°C followed by 40 
cycles of 95°C for 15 s and 60°C for 60 s. RTq-PCR quantification of miR 
expression was performed using TaqMan MicroRNA® Assays (Applied 
Biosystems) according to the manufacturer’s protocol. RNU19 was used 
as endogenous control to normalize miR expression. All reactions were 
performed in duplicate.
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The sequences of primers used for RTq-PCR were listed in 
Supplementary Table 6, available at Carcinogenesis Online.
Lysate preparation and immunoblotting analysis
Cells were lysed in buffer with 50 mM Tris–HCl pH 8, with 1% NP-40 (Igepal 
AC-630) 150 mM NaCl, 5 mM EDTA and fresh protease inhibitors. Extracts 
were sonicated for 10  s and centrifuged at 12 000× rpm for 10  min to 
remove cell debris. Protein concentrations were determined by colorimet-
ric assay (Bio-Rad).
Western blotting was performed using the following primary anti-
bodies: mouse monoclonal anti-Gapdh (Santa Cruz Biotechnology), 
mouse monoclonal anti-PR (Santa Cruz Biotechnology), rabbit polyclonal 
anti-p21 (Santa Cruz Biotechnology) and rabbit polyclonal anti-PARP 
(Cell Signaling).
Secondary antibodies used were goat anti-mouse, goat anti-rabbit, 
conjugated to horseradish peroxidase (Amersham Biosciences).
Immunostained bands were detected by chemiluminescent 
method (Pierce).
Results
Leucocyte miRNAs differentially expressed in 
ORDET samples
The baseline characteristics did not differ between the 191 
breast cancer cases and 191 controls: age at recruitment as well 
as age at menarche and age at first birth were not statistically 
associated to the case–control status as well as other reproduc-
tive, hormonal and life-style risk factors that could have repre-
sented confounders of the studied association (Supplementary 
Table 1, available at Carcinogenesis Online).
When we conducted class  comparisons to identify differ-
entially expressed miRNAs, we first performed a moderated t 
test (27) for each miRNA on all 382 premenopausal women. In 
our analysis, we included the top-ranked 20 miRNAs (ranked 
according to the FDR values): the difference in miRNA expres-
sion between cases and controls was balanced between up- and 
downregulation with 11 miRNAs downregulated and 9 upregu-
lated (see Supplementary Table  2, available at Carcinogenesis 
Online). Among the upregulated miRNAs, miR-513c-5p was 
characterized by the lowest FDR (close to 8%), resulting in the 
most statistically significant differentially expressed miRNA. 
Among the same group of upregulated miRNAs, miR-513a-5p 
ranked second together with the downregulated miR-431, miR-
550 and miR-23b (all at 13% FDR). An examination of miRNA 
expression of the 20 top-ranked miRNAs revealed that, among 
the upregulated miRNAs in candidate breast cancer versus con-
trol women, the first and second ranked miRNAs, miR-513c-5p 
and the miR-513a-5p together with miR-513b-5p belonged to a 
subfamily member of a miR-506-514 cluster located on the X 
chromosome, whose oncogenic role has been already well char-
acterized in melanoma (29,30). Figure  1A shows the heatmap 
of the all the 20 top-ranked miRNA profiles following an unsu-
pervised hierarchical clustering analysis. The heatmap revealed 
that the three miRNAs were also grouped together in one of the 
two largest clusters identified across the 20 top-ranked miRNAs. 
In order to better characterize the identified miRNA signature 
in breast cancer, we used data from the METABRIC cohort. As 
it is displayed in Principal Component Analysis (Figure 1B), the 
signature was moderately able to discriminate non-tumoral 
versus tumoral tissues. Moreover, in the METABRIC breast can-
cer patients higher values of miR-513a-5p in the tumor tissue 
were associated to a poor prognosis at univariate level as well 
as adjusting for clinical covariates, such as T,N, stage, age, hysto-
type, menopause status and ER, PR and HER2 status (Figure 1C).
In Table  1, we describe the most significant cancer pre-
dicted pathways targeted by miR-513a-5p, miR-513b-5p and 
miR-513c-5p. It is worth noting that the pathways identified by 
the three differentially upregulated miRNAs were very similar 
and related to both breast cancer and more general cancer de-
velopment (e.g. ErbB, mTOR, TGFb and Wnt pathways) (31–35). We 
then also observed that the three miRNAs targeted pathways also 
related to insulin and other endocrine/metabolic pathways recog-
nized in the ORDET cohort, as well as in other studies as pathways 
involved in breast cancer development (10,32,36). We repeated 
the prediction miR-513a-5p pathways analysis using data from 
the METABRIC study. First we identified putative targets of miR-
513a-5p predicted in at least three softwares using miRWALK2.0 
prediction tool. Then we split patients basing on their zscores as 
defined in KM curves. The Spearman’s correlation coefficient was 
used to select negative correlated gene targets separately in the 
two subgroups of patients. ConsensusPathDB (37) was interro-
gated for a pathway analysis of the identified genes.
Results of this analysis indicated that miR-513a-5p also in 
that cohort modulates the activation of those pathways observed 
in the ORDET cohort and associated to cancer development 
(Supplementary Tables 3 and 4, available at Carcinogenesis Online).
To identify and quantify the potential association between 
the 20 top-ranked miRNAs with breast cancer risk, we performed 
first an univariate and then a fully adjusted logistic regression 
analysis on all the considered miRNAs. We observed that among 
all the miRNAs, only the miR-513a-5p differential expression 
was directly and significantly associated with risk of breast can-
cer. The univariate and the multivariate odds ratios were similar 
ranging between 1.62 (95% CI 1.08–2.43; P = 0.018) to 1.69 (95% 
CI 1.08–2.64; P = 0.0293) adjusted for age, age at menarche, age 
at first pregnancy, BMI, smoking, alcohol intake, fasting glucose, 
IGF-1, insulin, progesterone, estradiol and total testosterone as 
breast cancer risk factors earlier reported in the ORDET cohort.
Previous reports from the ORDET cohort indicated serum sex 
steroids were implicated in breast cancer development (11,13), 
thus, we examined the association between progesterone, serum 
total testosterone and estradiol and each single miRNA expression 
first at univariate and then at multivariate level. We excluded from 
this analysis the let-7c* as it has been define a dubious miRNA 
(38). While both serum progesterone and testosterone were not 
associated with breast cancer risk in the present set of the ORDET 
cases and controls [progesterone OR = 0.99 (95% CI 0.64–1.57); tes-
tosterone OR = 1.10 (95% CI 0.71–1.71)], at univariate level, miR-
513a-5p showed the strongest association with serum levels of 
progesterone at borderline statistical significance (β coeff. = 0.39; 
P  =  0.07) (Supplementary Table  5, available at Carcinogenesis 
Online). Subsequently, we performed a multivariate analysis of 
the top-ranked miRNAs in association with Progesterone (Table 2) 
with the inclusion of the same potential confounders used for the 
odds ratio assessment (Univariate analysis results are included 
in Supplementary Table  5, available at Carcinogenesis Online). 
Interestingly, we observed that, again, in both univariate and mul-
tivariate analysis, miR-513a-5p was the only miRNA associated 
with progesterone level and this time the positive association was 
stronger and reached the statistical significance (β coeff. = 0.55; 
P  =  0.04). When subsequently, we examined the association 
between miR-513a-5p and each single covariate, adjusting the 
point estimates for all the other variables, the data showed that 
miR-513a-5p upregulation was significantly and independently 
associated with testosterone and progesterone serum levels 
(Table 3) (Box plots are also included as Supplementary Figure 1A 
and B, available at Carcinogenesis Online).
In order to understand whether miR-513a-5p expression was 
modulated in different histological subgroups, considering the 
unavailability of the breast cancer tissue samples of the ORDET 
study, we conducted the analysis within the METABRIC cohort. 
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In that cohort we observed higher miRNA513a-5p expression 
level in HER2 and a lower expression in the luminal A subgroup 
(Supplementary Figure  2A, available at Carcinogenesis Online). 
Furthermore, we did not observe any statistically significant 
difference across menopausal status (Supplementary Figure 2B, 
available at Carcinogenesis Online).
At the end of this phase of analysis, we observed that:
a)  MiR-513a-5p expression was directly and significantly 
associated with almost 70% increase in breast cancer risk;
b)  MiR-513a-5p expression was directly and significantly asso-
ciated with progesterone and testosterone serum levels
We then conducted two different in vitro experiments to clarify 
the role of miR-513a-5p as simultaneous risk factor for breast 
cancer and endocrine modulator.
Figure 1. (A) Heatmap of top ranked 20 miRNAs from premenopausal samples. The heatmap provides insight into the data structure for each microRNA and samples. 
We used red and green colors for defining low and high expression values. The blue represents the cases and yellow represents the controls. The clustering methods 
partitioned the dataset into three clusters identified on the left side of the figure. Each miRNA is listed on the right side. (B) Principal component analysis of the miRNAs 
signature from METABRIC breast cancer patient sample analysis. (C) Breast cancer survival data based on miR-513a-5p low and high expression. Higher values of miR-
513a-5p were associated to a poor prognosis from Kaplan–Meier method and multivariate Cox proportional-hazards regression. Several clinical variables, such as T, N, 
stage, age, hystotype, menopause status and ER, PR, HER2 receptors, were included in the multivariate model.
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MiR-513a-5p impinges on progesterone 
receptor protein expression in breast 
cancer cells
Recent data from experimental studies showed that miR-
513a-5p reduces the expression of PR through its direct bind-
ing to the 3′UTR of PR mRNA (39). The human PR gene holds a 
long 3′UTR sequence, about 13 kb in length, containing several 
putative miRNA target sites, thereby suggesting an important 
involvement of this region in the control of PR translation (40).
Due to the previously reported evidences about miR-513a-5p 
in the regulation of PR levels, we aimed to confirm this direct 
effect in our cellular model (39). In particular, we initially ana-
lysed the expression levels of miR-513a-5p in two luminal breast 
cancer cell lines, MCF7 and T47D (ER+ and PR+) (Figure 2A), that 
constitutively expressed high levels of PR. MCF-7 cell line, which 
presented the lowest levels of miR-513a-5p, has been chosen 
as cellular system in which to perform ectopical expression of 
miR-513a-5p. As shown in Figure 2B and C, the over-expression 
of miR-513a-5p determined a significant reduction in PR protein 
and mRNA levels compared to the relative control. This inhibi-
tory effect on PR protein expression levels occurred also in two 
additional luminal breast cancer cell lines, ZR-75-1 and BT-474 
(Figure 2D). To better investigate the direct effect of miR-513a-5p 
on PR expression levels, we treated cells with estradiol (E2), that 
induces the transcription of PR gene. As it has been shown in 
Figure  2E and F, in a cellular context characterized by higher 
levels of PR, the inhibitory effect of miR-513a-5p on PR mRNA 
and protein levels was more pronounced. This also pairs with 
the striking reduction of mRNA levels of ATP1B1, a transcrip-
tional target of PR (Figure 2G). Conversely, the induction of PR 
and ATP1B1 was similar to the control cells in E2 treated MCF-7 
cells depleted for the miR-513a-5p expression (Figure  2H–J). 
Taken together, these findings contribute to establish PR as a 
direct target of miR-513a-5p in breast cancer cells.
In order to further characterize miR-513a-5p function in breast 
cancer, we performed in silico analysis for miR-513a-5p target genes. 
Among the list of the putative targets, EGFR and ERBB2 resulted to be 
the more interesting, in terms of number of software that predicted 
them and pathways involved in breast cancer (Supplementary 
Table 2. Multivariate analysis of miRNA signature and progesterone
miRNA β P value
hsa-miR-23b 0.28 0.3
hsa-miR-361-3p 0.2 0.43
hsa-miR-128 0 0.98
hsa-miR-1275 0.34 0.2
hsa-miR-197 0.31 0.23
hsa-miR-326 −0.1 0.71
hsa-miR-183* −0.05 0.85
hsa-miR-550* 0.19 0.49
hsa-miR-155 0.27 0.33
hsa-miR-370 0.31 0.25
hsa-miR-1254 0.31 0.25
hsa-miR-513a-5p 0.55 0.04
hsa-miR-513b 0.25 0.37
hsa-miR-513c 0.04 0.9
hsa-miR-654-3p –0.01 0.98
hsa-miR-431 0.1 0.7
hsa-miR-498 −0.2 0.46
hsa-miR-518d-3p −0.56 0.1
hsa-miR-92a −0.1 0.69
β values represent the expected change in log odds for a one unit of  
progesterone. High and low values were defined by positive and negative 
Z-scores progesterone was adjusted for BMI, age menarche, insulin, igf1, tts, 
glucose, age, full-term pregnancy, alcohol, age first birth, smoke and estradiol.
Table 3. Multivariate analysis of miR-513a-5p
β P value
BMI −0.26 0.33
Age menarche −0.26 0.29
Insulin −0.09 0.72
IGF1 −0.24 0.35
TTS 0.69 0.01
PG 0.55 0.04
E2 −0.4 0.14
Glucose −0.19 0.47
Age −0.14 0.59
Full-term pregnancy 0.31 0.23
Alcohol 0.35 0.16
Age first birth 0.2 0.42
Smoke 0.32 0.21
β values represent the expected change in log odds for a one unit of the  
variable. High and low values were defined by positive and negative Z-scores. 
Each variable was adjusted for the others.
Table  1. Cancer predicted pathways targeted by miR-513a-5p, 
miR-513b-5p and miR-513c-5p listed among the nine differentially 
upregulated miRNAs
microRNA Most significant predicted pathways P value
hsa-miR-513a-5p Pathways in cancer 3.3E–08
Wnt signalling pathway 1.1E–07
Hedgehog signalling pathway 1.7E–04
ErbB signalling pathway 1.7E–04
Insulin signalling pathway 2.6E–04
mTOR signalling pathway 1.5E–03
Chemokine signalling pathway 2.8E–03
TGF beta signalling pathway 2.5E–02
Metabolic pathways 4.1E–02
hsa-miR-513b-5p Pathways in cancer 1.5E–11
Wnt signalling pathway 5.4E–08
ErbB signalling pathway 5.9E–07
Insulin signalling pathway 6.4E–05
MAPK signalling pathway 1.3E–03
mTOR signalling pathway 4.3E–03
Hedgehog signalling pathway 4.7E–03
Metabolic pathways 4.7E–02
Cell cycle 3.9E–02
Chemokine signalling pathway 4.1E–02
TGF beta signalling pathway 4.1E–02
hsa-miR-513c-5p Wnt signalling pathway 9.7E–08
Pathways in cancer 2.9E–07
MAPK signalling pathway 7.3E–05
Hedgehog signalling pathway 2.7E–04
ErbB signalling pathway 3.8E–04
Insulin signalling pathway 2.1E–03
mTOR signalling pathway 6.4E–03
TGF beta signalling pathway 3.5E–02
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Figure 2. MiR-513a-5p impairs the expression of PR in luminal breast cancer cell lines. (A) qRT-PCR analysis of miR-513a-5p expression levels in MCF-7 and T47D cell 
lines. (B, C) Western blot analysis and qRT-PCR analysis of PR expression levels in MCF7 cells transiently transfected with miR-513a-5p mimic or control. (D) Western 
blot analysis of PR protein expression in ZR-75-1 and BT-474 breast cancer cell lines transiently transfected with miR-513a-5p mimic or control. (E) Western blot analy-
sis of PR protein expression in serum-starved MCF-7 cells treated for 48 h with 10 nM E2 upon miR-513a-5p over-expression. (F, G) qRT-PCR analysis of PR and ATP1B1 
expression levels in serum-starved MCF-7 cells treated for 48h with 10nM E2 upon miR-513a-5p over-expression. (H) Western-blot analysis of PR protein expression in 
serum-starved MCF-7 cells treated for 48 h with 10 nM E2 upon miR-513a-5p inhibition (inh miR-513a-5p). (I, J) qRT-PCR analysis of PR and ATP1B1 expression levels in 
serum-starved MCF-7 cells treated for 48 h with 10 nM E2 upon miR-513a-5p inhibition (inh miR-513a-5p). *P < 0.05.
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Figure 3A, available at Carcinogenesis Online). To verify the binding 
of miR-513a-5p on EGFR and ERBB2 3′UTRs, we evaluated their 
protein expression levels in ZR-75-1 breast cancer cells upon miR-
513a-5p expression. As shown in Supplementary Figure 3B, avail-
able at Carcinogenesis Online, we observed a significant reduction 
in EGFR and ERBB2 protein levels, indicating an inhibitory effect 
of miR-513a-5p on these two receptors whose involvement in 
breast cancer progression is well established. Moreover, to assess 
the ability of miR-513a-5p to bind to EGFR 3′UTR we performed 
luciferase assays using a reporter construct with the full-length 
3′UTR of EGFR. As shown in Supplementary Figure 3C, available at 
Carcinogenesis Online, miR-513a-5p significantly reduced the rela-
tive luciferase activity of the reporter, indicating a direct inhibitory 
effect of miR-513a-5p on EGFR mRNA translation.
MiR-513a-5p renders breast cancer cells 
more resistant to starvation stress
There is still scarce evidence of the functional effects of miR-
513a-5p in breast cancer. To this purpose we aimed to test the 
effect induced either by miR-513a-5p ectopic expression or its 
depletion in MCF7 cells. No effect on cell viability was observed 
under standard cell culture condition (Supplementary Figure 4A 
and B, available at Carcinogenesis Online). Strikingly miR-513a-5p 
impacted the cell response upon serum-starvation. MCF7 under-
went growth arrest and apoptosis upon treatment with E2 or 
progesterone in condition of serum starvation, which was typ-
ical cellular response to stress induced by deprivation of nutri-
ents (41,42). This led to the increase of p21 and cleaved PARP 
protein expression, respectively (Figure 3A–C). MiR-513a-5p ec-
topic expression increased cell resistance to serum starvation. 
This also led to lower p21 and cleaved PARP protein levels, when 
compared with control cells (Figure 3A–C).
Upon E2 or progesterone treatment, we found an induction 
of PR expression (Figure 3A–C upper panels lane 3). Ectopic ex-
pression of miR-513a-5p mimic significantly reduced the ex-
pression of PR (Figure 3A–C upper panels lane 4).
In serum starvation condition, being it a stress condi-
tion, we observed a reduction in PR protein levels upon miR-
513a-5p over-expression only upon stimulation of PR expression 
(Figure 3A–C). It is possible that in serum starvation conditions 
miR-513a-5p is not able to affect the basal levels of PR.
Figure 3. MiR-513a-5p increases MCF-7 cells resistance to serum-starvation stress. (A, B) Western blot analysis of PR, p21 and cleaved PARP proteins expression in 
serum-starved MCF-7 cells treated for 48 h with 10 nM E2 upon miR-513a-5p over-expression. (C) Western blot analysis of PR and cleaved PARP proteins expression in 
serum-starved MCF-7 cells treated for 48 h with 10 nM P4 upon miR-513a-5p over-expression. 
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These findings originally highlight a putative oncogenic role 
of miR-513a-5p in breast cancer cells.
At the end of this phase of experimental studies, we 
understood that:
• Progesterone receptor is a direct target of miR-513a-5p
• The experimental data have pointed out a specific putative 
oncogenic function of miR-513a-5p corroborating its role as 
potential breast cancer risk factor.
Discussion
The present study has identified miR-513a-5p as prediagnostic 
miRNA that, when upregulated is able to reduce PR levels and poten-
tially to decrease the biological function of progesterone. At the 
same time, the significant upregulation of miR-513a-5p in women 
candidate to develop breast cancer many years before the on-set 
of the disease, makes this miRNA an early, long-term biomarker of 
breast cancer risk in premenopausal women. The two combined 
observations provide evidence that reduction in progesterone bio-
logical activity may represent a risk factor for breast cancer.
We assessed miRNAs in leukocytes: the high blood stability 
of miRNAs, their resistance to RNA degradation and their repro-
ducible detection make miRNAs suitable biomarker candidates 
(43). The relation between leukocytes intervention and inflam-
mation in tumor development has been identified since the 
beginning of the 19th century. However, only in the last 10 years, 
experimental and clinical studies have identified inflammation 
as a major player in tumorigenesis, and some of the key basic 
mechanisms have been clarified (44). Inflammation responsibil-
ity in different aspects of tumorigenesis is now accepted, and 
it is now clear that an inflammatory macro- as well as micro-
environment are very relevant components of cancer develop-
ment (45). Chronic inflammation can be induced by endocrine 
and metabolic cancer risk factors (i.e. obesity, altered glucose 
metabolism, etc) and by environmental exposures (i.e. expo-
sure to asbestos, pollutants). These same pro-inflammatory fac-
tors have been reflected into specific deregulation of miRNA in 
peripheral leukocytes (46). It has been indicated that an inflam-
matory microenvironment can lead to a raise in mutation 
rates together with amplifying the proliferation of transformed 
cells. As matter of fact, inflammatory cells may produce reac-
tive oxygen species (ROS) and reactive nitrogen intermediates 
inducing DNA damage and genomic instability (47).Thus, in 
our study, leukocytes could in fact represent expression of that 
chronic inflammation status leading many years later to breast 
cancer development. Progesterone shows to have both anti-
inflammatory activity and to inhibit oncogenic pathways (48). 
Thus, results of our study are in agreement with the evidence 
produced by leukocytes: low expression of PR could represent an 
‘intracrine’ facilitating condition for cancer development.
As mentioned above, the role of progesterone in the natural 
history of breast cancer has been a scientific unresolved issue in 
particular for premenopausal women. In these women, the role 
of progesterone in breast cancer development has been chal-
lenged by different sources of variability such as the variability 
of progesterone serum concentrations over the menstrual cycle 
and the variability of cycle length within and between individ-
uals (14). However, in spite of these limitations, the European 
Prospective Investigation on Cancer and Nutrition (EPIC), which 
is one of the largest prospective cohort studies on cancer aeti-
ology, investigated the association between sex steroid hor-
mones and breast cancer occurrence in premenopausal women 
(12). The study observed a statistically significant inverse 
relationship between serum levels of progesterone and breast 
cancer incidence. The study replicated the results of the first 
7-year follow-up of the ORDET cohort study (11). An additional 
analysis conducted on a new follow-up of the ORDET cohort did 
not observe any risk associated with progesterone serum lev-
els (13). The last published report on progesterone and breast 
cancer risk described the pooled analysis of the seven largest 
prospective cohort studies on hormones and breast cancer risk 
(10) also confirmed the lack of association between progesterone 
levels and risk of breast cancer.
When we looked at the PR as main outcome of the miR-
513a-5p functional activity, the scientific literature included 
mainly studies describing the correlation between PR expression 
and different miRNAs, but only few evidences about direct effect 
of miRNAs on PR expression. In particular, in human breast can-
cer cells MCF-7 it has been demonstrated that PR expression 
was also negatively regulated by the direct binding of miRNA-
181 and miRNA-26a on its 3′UTR (49). Recently Cochrane and 
coworkers, reported a feedback loop mechanism through which 
PR regulates its own levels by promoting the expression of miR-
513a-5p that in turns targets the PR 3′UTR (39). In particular the 
authors observed that in luminal breast cancer cells, upon pro-
gestin treatments, there was an increase in miR-513a-5p expres-
sion levels and a concomitant reduction in the protein levels of 
PR (39). This reduction was partially due to the direct binding of 
miR-513-5p on three binding sites located in PR 3′UTR (39). In 
our study we observed that miR-513a-5p determined the reduc-
tion in PR levels, in particular upon E2-mediated stimulation of 
PR gene transcription, impinging on PR signaling pathway and 
concomitantly a significant induction of resistance to starvation 
stress in breast cancer cell lines, supporting a direct potential 
oncogenic role for miR-513a-5p. The association between miR-
513a-5p and elevated levels of serum progesterone observed in 
our cohort is in agreement with the positive effect of proges-
tin treatments on miR-513a-5p expression levels described by 
Cochrane et al. It may also represent a potential positive feed-
back mechanism to compensate for the reduction in PR at the 
beginning of a process that later will create the condition for 
breast cancer development.
The association between miR-513a-5p with elevated levels of 
serum testosterone represents a new finding to be subsequently 
explored. Elevated levels of testosterone have been consistently 
found associated to breast cancer development in different 
studies, in pre- and postmenopausal women and in different 
populations. The association of miR-513a-5p upregulation with 
elevated circulating testosterone levels may delineate a risk pro-
file to be better characterized and validated in different prospec-
tive cohort studies.
Limitations of this investigation warrant consideration. The 
adopted study design was powerful to infer on the etiological 
role of miRNAs on breast cancer risk definition and the follow-
up was crucially long to adapt the study results to the natural 
history of the disease. However, we recognized that our infer-
ence were done on blood sample collected only once in the 
ORDET participants. Nevertheless, miRNAs are characterized by 
small intra-individual variability (50) showing that miRNAs have 
great potential as reliable blood biomarkers of early signs of dis-
ease development. We are also aware that in the first set of bio-
informatics analysis FDRs differentiating the level of expression 
for the 20 top-ranked miRNAs were not characterized by a high 
level of statistical difference. In cancer prevention, which usu-
ally concerns with healthy individuals and very long follow-up, 
one should expect to observe relatively weak statistical signifi-
cant differences especially in dealing with serum samples and 
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not with tissue biopsies. In these studies, based on thousands of 
molecular variables, bioinformatic analysis and related applied 
statistics may provide general orientation for further investi-
gations with the application of different strategies to validate 
the study results. Because of that, we have validated the find-
ings from the ORDET cohort through both the use of a differ-
ent cohort study, the METABRIC study, where we repeated part 
of the bioinformatic and biostatistical analyses and the specific 
design of experimental studies. Thus, the confirmatory results 
observed by these two different contexts validated the ORDET 
outcomes beyond the level of the initial statistical significance.
In summary, results of the present study may impinge dif-
ferent aspects of breast cancer development. The identification 
of miR-513a-5p with its oncogenic potential further validates 
both the use of miRNAs as long-term biomarker of breast cancer 
risk and the use of miRNAs to identify the pathways implicated 
in early breast cancer development. In this particular case, the 
reduction in PR level exerted by the upregulated miR-513a-5p 
may shed new light on the effect of natural progesterone in 
breast cancer etiology.
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